Entero Healthcare Solutions Limited — PPTs, 12-02-2026: Investor Presentation

Entero Healthcare Solutions reported robust Q3FY26 results, with revenue growing 25.6% YoY to Rs 1,707 Cr, driven by strong organic growth of 14.2% YoY. Gross margin improved to 10.1% (+30bps YoY) and EBITDA margin reached 4.0% (+29bps YoY). Profit after tax attributable to owners increased 8.6% to Rs 27.6 Cr. For the nine months, revenue rose 24.6% to Rs 4,681 Cr, and PAT to owners increased 25.9% to Rs 87.0 Cr.

The company achieved positive operating cash flow of Rs 49 Cr in Q3FY26, reflecting improved working capital efficiency and RoCE of 14.8%.

Entero is strategically focused on the MedTech segment, having closed all major, margin-accretive acquisitions, including Anand Chemiceutics. Three MedTech acquisitions were completed in Q3FY26. Management indicates these moves position the company to accelerate growth and expand margins, with MedTech revenue projected to exceed Rs 1,000 Cr next fiscal year. Entero continues to outperform industry growth.